Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 8/20 | 0.77 |
| ▸ | CA9 | Q16790 | 8/20 | 0.77 |
| ▸ | CA1 | P00915 | 6/20 | 0.77 |
| ▸ | CA4 | P22748 | 5/20 | 0.77 |
| ▸ | CA5A | P35218 | 5/20 | 0.77 |
| ▸ | CA7 | P43166 | 5/20 | 0.77 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.77 |
| ▸ | CA3 | P07451 | 4/20 | 0.77 |
| ▸ | CA5B | Q9Y2D0 | 4/20 | 0.77 |
| ▸ | CA6 | P23280 | 4/20 | 0.77 |
| ▸ | CA2 | P00918 | 3/20 | 0.77 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.58 |
| ▸ | MAOB | P27338 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | GLA | P06280 | 3/20 | 0.53 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.53 |
| ▸ | HPGD | P15428 | 3/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28776384 | 0.87 | CA12 (1.00) | CA12CA9CA1CA4CA5A | |
| SCHEMBL28085698 | 0.82 | CA12 (0.64) | CA12CA9CA1CA4CA5A | |
| SCHEMBL28751224 | 0.82 | CA12 (0.58) | CA12CA9CA1CA4CA5A | |
| SCHEMBL4013360 | 0.81 | CA12 (0.62) | CA12CA9CA1CA4CA5A | |
| SCHEMBL2978737 | 0.81 | CA12 (0.62) | CA12CA9CA1CA4CA5A | |
| SCHEMBL3326190 | 0.81 | CA12 (0.77) | CA12CA9CA1CA4CA5A | |
| SCHEMBL29603488 | 0.81 | CA12 (0.77) | CA12CA9CA1CA4CA5A | |
| SCHEMBL8750116 | 0.81 | CA12 (0.62) | CA12CA9CA1CA4CA5A | |
| SCHEMBL24017191 | 0.79 | CA12 (0.60) | CA12CA9CA1CA4CA5A | |
| SCHEMBL16271239 | 0.78 | SRD5A1 (0.60) | CA12CA9CA1CA4CA5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 691 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250290918-A1 | METHODS FOR ASSESSING CELL SURFACE GLYCOSYLATION | JUNO THERAPEUTICS, INC. (US) | 2025-09-18 | — | — | US | claimed |
| US-11796534-B2 | Methods for assessing cell surface glycosylation | JUNO THERAPEUTICS, INC. (US) | 2023-10-24 | — | — | US | claimed |
| WO-2022015162-A1 | QUANTITATIVE DETECTION OF REDUCING SUGARS | DUCARES B.V. (NL) | 2022-01-20 | — | — | WO | claimed |
| US-20210255173-A1 | METHODS FOR ASSESSING CELL SURFACE GLYCOSYLATION | JUNO THERAPEUTICS, INC. (US) | 2021-08-19 | — | — | US | claimed |
| EP-3610261-A1 | METHODS FOR ASSESSING CELL SURFACE GLYCOSYLATION | Juno Therapeutics, Inc. (US) | 2020-02-19 | — | — | EP | claimed |
| CN-110709700-A | Method for evaluating cell surface glycosylation | 朱诺治疗学股份有限公司 | 2020-01-17 | — | — | CN | claimed |
| WO-2018191723-A1 | METHODS FOR ASSESSING CELL SURFACE GLYCOSYLATION | JUNO THERAPEUTICS, INC. (US) | 2018-10-18 | — | — | WO | claimed |
| WO-2008130924-A2 | ISOTOPICALLY-LABELED GLYCANS | MOMENTA PHARMACEUTICALS, INC. (US) | 2008-10-30 | — | — | WO | claimed |
| EP-0347771-A2 | Device for enhancing fluorescence and kinetics and methods of using the device | Becton, Dickinson and Company (US) | 1989-12-27 | — | — | EP | claimed |
| US-4798788-A | Processes and materials for carrying out microchemical and microbiological tests | DADE BEHRING INC. | 1989-01-17 | — | — | US | claimed |
| US-20260146040-A1 | USE OF CASEINOLYTIC PROTEASE P FUNCTION AS A BIOMARKER OF DRUG RESPONSE TO IMIPRIDONE-LIKE AGENTS | Madera Therapeutics, LLC (US) | 2026-05-28 | — | — | US | disclosed |
| US-20260140105-A1 | METHODS AND SYSTEMS FOR ANALYTE DETECTION AND ANALYSIS | ULTIMA GENOMICS INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260116065-A1 | SYSTEMS AND METHODS FOR SPATIAL SCREENING OF ANALYTES | ULTIMA GENOMICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260109962-A1 | METHOD FOR THE PRODUCTION OF AN ENZYMATIC COMPOSITION COMPRISING A RECOMBINANT ENDOPEPTIDASE | NEMYSIS LIMITED (IE) | 2026-04-23 | — | — | US | disclosed |
| US-20260103741-A1 | NUCLEIC ACID CLONAL AMPLIFICATION AND SEQUENCING METHODS, SYSTEMS, AND KITS | ULTIMA GENOMICS INC (US) | 2026-04-16 | — | — | US | disclosed |
| US-5190974-A | Analgesics | ROUSSEL UCLAF (FR) | 1993-03-02 | — | — | US | disclosed |
| EP-0452330-A4 | METHOD AND APPARATUS FOR DIAGNOSING INTRACELLULAR PARASITE INFECTIONS USING AN ENZYME DETECTION SYSTEM | — | 1992-10-14 | — | — | EP | disclosed |
| EP-0452330-A1 | METHOD AND APPARATUS FOR DIAGNOSING INTRACELLULAR PARASITE INFECTIONS USING AN ENZYME DETECTION SYSTEM | TOTEM HEALTH SCIENCES, INC. (CA) | 1991-10-23 | — | — | EP | disclosed |
| WO-1990004644-A1 | METHOD AND APPARATUS FOR DIAGNOSING INTRACELLULAR PARASITE INFECTIONS USING AN ENZYME DETECTION SYSTEM | TOTEM HEALTH SCIENCES, INC. (CA) | 1990-05-03 | — | — | WO | disclosed |
| US-4839358-A | ANALGESICS, ANTIDEPRESSANTS, ANTIANXIETY AGENTS | ROUSSEL UCLAF (FR) | 1989-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260109962-A1 | METHOD FOR THE PRODUCTION OF AN ENZYMATIC COMPOSITION COMPRISING A RECOMBINANT ENDOPEPTIDASE | CMA1, RNGTT, ENGASE | CA12 3615/4885CA9 1967/4885CA1 2665/4885 |
| US-20260140105-A1 | METHODS AND SYSTEMS FOR ANALYTE DETECTION AND ANALYSIS | SRMS, CFD, STUB1 | CA12 46/4885CA9 742/4885CA1 341/4885 |
| US-20260103741-A1 | NUCLEIC ACID CLONAL AMPLIFICATION AND SEQUENCING METHODS, SYSTEMS, AND KITS | DNMT3A, POLB, POLL | CA12 2503/4885CA9 1572/4885CA1 3679/4885 |
| US-20260146040-A1 | USE OF CASEINOLYTIC PROTEASE P FUNCTION AS A BIOMARKER OF DRUG RESPONSE TO IMIPRIDONE-LIKE AGENTS | CTRB1, CTRB2, CPN1 | CA12 775/4885CA9 628/4885CA1 672/4885 |
| US-20260116065-A1 | SYSTEMS AND METHODS FOR SPATIAL SCREENING OF ANALYTES | APP, KLK3, HAVCR2 | CA12 67/4885CA9 818/4885CA1 794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.